Who we are

RECOGNIZED LEADERS IN CROSS BORDER AND LOCAL MARKETS

management team

Adam Stone
Adam Stone
Interim Chief Executive Officer
see bio
Brianne Jahn
Brianne Jahn
Chief Business Officer
see bio
Ehong (Maggie) Gu
Ehong (Maggie) Gu
Interim Chief Financial Officer
see bio
Michael Humphries, FRCP
Michael Humphries, FRCP
Chief Scientific Advisor
see bio
Levvy Lv, D. Eng
Levvy Lv, D. Eng
SVP, Global Head of Development
see bio
Ji Chen
Ji Chen
SVP, General Counsel
see bio

BOARD OF DIRECTORS

Konstantin Poukalov
Konstantin Poukalov
Founder, Executive Chairman
see bio
Adam Stone
Adam Stone
see bio
Neil Kumar, Ph.D.
Neil Kumar, Ph.D.
see bio
Tassos Gianakakos
Tassos Gianakakos
see bio
Susan Silbermann
Susan Silbermann
see bio
Wei Wei Chen
Wei Wei Chen
see bio

SCIENTIFIC ADVISORY BOARd

Mathias Hukkelhoven, Ph.D
Mathias Hukkelhoven, Ph.D
R&D Strategy Advisor
see bio
Elliott Levy, MD
Elliott Levy, MD
R&D Strategy Advisor
see bio
Zhao Yan, MD, EMBA
Zhao Yan, MD, EMBA
R&D Strategy Advisor
see bio

Program Partners

BridgeBio Pharma

BridgeBio’s mission is to find, develop, and deliver breakthrough medicines for genetic diseases to patients as quickly and safely as possible. The company creates a bridge from remarkable advancements in genetic science to patients with unmet needs via the entrepreneurial engine required to make life-changing medicines as rapidly as possible.

Navire Pharma

Navire, an affiliate of BridgeBio Pharma, is harnessing advances in the understanding of the role of SHP2 (Src homology region 2-containing protein tyrosine phosphatase) in cancer signaling to develop novel therapies for rare and difficult-to-treat cancers. The company develops small molecules inhibitors to SHP2, a phosphatase that mediates signaling of multiple pathways harnessed by tumors, thereby decreasing tumor growth while also enhancing patients’ immune response.

QED Therapeutics

QED, an affiliate of BridgeBio Pharma, focuses on precision medicine for FGFR-driven cancers and diseases. QED, derived from the Latin “Quod Erat Demonstrandum” means “Thus, It Has Been Proven.” The company is focused on the development of infigratinib, a selective FGFR1-3 inhibitor.

Tarsus Pharmaceuticals, Inc.

Tarsus Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company that applies proven science and new technology to revolutionize treatment for patients, starting with eye care. It is advancing its pipeline to address a number of diseases with high unmet need across a range of therapeutic categories, including eye care, dermatology, and infectious disease prevention. Its lead product candidate, TP-03, is a novel therapeutic in Phase 2b/3 for the treatment of Demodex blepharitis. TP-03 is also being developed for the treatment of Meibomian Gland Disease.

Nanobiotix

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life. Incorporated in 2003, Nanobiotix is headquartered in Paris, France and Cambridge, Massachusetts (United States). The company also has subsidiaries in France, Spain, and Germany.

Lyra Therapeutics

Lyra Therapeutics, Inc. is a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, local delivery of medications to diseased tissues not accessible with conventional therapeutic approaches. Lyra’s XTreo™ platform is comprised of a biocompatible mesh scaffold, an engineered elastomeric matrix and a versatile polymer-drug complex. The company’s current pipeline of therapeutics target tissues deep in the ear, nose and throat passages and are designed to deliver continuous drug therapy for months following a single non-invasive, in-office administration. Lyra’s lead product candidate, LYR-210, is in late-stage clinical development for the treatment of chronic rhinosinusitis and is designed to deliver up to six months of continuous anti-inflammatory drug therapy to the sinonasal passages.

Landos Biopharma

Landos Biopharma is a clinical-stage biopharmaceutical company utilizing its LANCE A.I. platform to discover and develop novel oral therapeutics for patients with autoimmune diseases. LANCE has discovered new mechanisms of action, including the LANCL2, NLRX1 and PLXDC2 immunometabolic pathways. Landos Biopharma has 17 active development programs targeting these novel pathways at the interface of immunity and metabolism. Lead asset omilancor is a novel gut-restricted small molecule drug candidate for the treatment of ulcerative colitis, Crohn’s disease and Eosinophilic Esophagitis that targets the LANCL2 pathway. NX-13 is a novel, gut-restricted small molecule drug candidate for the treatment of inflammatory bowel disease, that targets the NLRX1 pathway. Additional candidates are in development for the treatment of lupus nephritis, rheumatoid arthritis, multiple sclerosis, and diabetes.